menu

Diving into Developments in Ovarian Cancer Detection

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Diving into Developments in Ovarian Cancer Detection

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • In Partnership with

  • Overview

    Recently the FDA approved a “Glowing Tumor” imaging drug to help oncologists better identify ovarian cancer cells using an approach pioneered by surgeons at Penn Medicine. Joining Dr. Charles Turck to discuss this recent approval and fluorescence-guided, intraoperative imaging is Dr. Janos Tanyi, Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • In Partnership with

  • Overview

    Recently the FDA approved a “Glowing Tumor” imaging drug to help oncologists better identify ovarian cancer cells using an approach pioneered by surgeons at Penn Medicine. Joining Dr. Charles Turck to discuss this recent approval and fluorescence-guided, intraoperative imaging is Dr. Janos Tanyi, Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania.

Facebook Comments

Schedule5 Dec 2022